Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?

Author(s): Rigas G. Kalaitzidis*, Thalia Panagiotopoulou, Dimitrios Stagikas, Kosmas Pappas, Olga Balafa, Moses S. Elisaf

Journal Name: Current Vascular Pharmacology

Volume 18 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

The incidence of hypertension (HTN) and its cardiovascular (CV) complications are increasing throughout the world. Blood pressure (BP) control remains unsatisfactory worldwide. Medical inertia and poor adherence to treatment are among the factors that can partially explain, why BP control rate remains low. The introduction of a method for measuring the degree of adherence to a given medication is now a prerequisite. Complex treatment regimes, inadequate tolerance and frequent replacements of pharmaceutical formulations are the most common causes of poor adherence. In contrast, the use of stable combinations of antihypertensive drugs leads to improved patient adherence.

We aim to review the relationships between arterial stiffness, cognitive function and adherence to medication in patients with HTN.

Large artery stiffening can lead to HTN. In turn, arterial stiffness induced by HTN is associated with an increased CV and stroke risk. In addition, HTN can induce disorders of brain microcirculation resulting in cognitive dysfunction. Interestingly, memory cognitive dysfunction leads to a reduced adherence to drug treatment. Compliance with antihypertensive treatment improves BP control and arterial stiffness indices. Early treatment of arterial stiffness is strongly recommended for enhanced cognitive function and increased adherence.

Keywords: Hypertension, arterial stiffness, cognitive dysfunction, adherence to medication, cardiovascular disease, arterial pressure.

[1]
Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134(6): 441-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018912] [PMID: 27502908]
[2]
Cifkova R, Fodor G, Wohlfahrt P. Changes in hypertension prevalence, awareness, treatment, and control in high-, middle-, and low-income countries: an update. Curr Hypertens Rep 2016; 18(8): 62.
[http://dx.doi.org/10.1007/s11906-016-0669-y] [PMID: 27372446]
[3]
Hales CM, Carroll MD, Simon PA, Kuo T, Ogden CL. Hypertension prevalence, awareness, treatment, and control among adults aged ≥18 years - Los Angeles county, 1999-2006 and 2007-2014. Morb Mortal Rep 2017; 66(32): 846-9.
[http://dx.doi.org/10.15585/mmwr.mm6632a3] [PMID: 28817553]
[4]
Kurdi AI, Chen LC, Elliott RA. Exploring factors associated with patients’ adherence to antihypertensive drugs among people with primary hypertension in the United Kingdom. J Hypertens 2017; 35(9): 1881-90.
[http://dx.doi.org/10.1097/HJH.0000000000001382] [PMID: 28441185]
[5]
Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38): 2940-8.
[http://dx.doi.org/10.1093/eurheartj/eht295] [PMID: 23907142]
[6]
Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29(3): 610-8.
[http://dx.doi.org/10.1097/HJH.0b013e328342ca97] [PMID: 21157368]
[7]
Lee HJ, Jang SI, Park EC. Effect of adherence to antihypertensive medication on stroke incidence in patients with hypertension: a population-based retrospective cohort study. BMJ Open 2017; 7(6) e014486
[http://dx.doi.org/10.1136/bmjopen-2016-014486] [PMID: 28674133]
[8]
Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003; 35(3): 207.
[PMID: 14562485]
[9]
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353(5): 487-97.
[http://dx.doi.org/10.1056/NEJMra050100] [PMID: 16079372]
[10]
Monroe AK, Pena JS, Moore RD, et al. Randomized controlled trial of a pictorial aid intervention for medication adherence among HIV-positive patients with comorbid diabetes or hypertension. AIDS Care 2017; 30(12): 1-8.
[PMID: 28793785]
[11]
Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens 2017; 35(6): 1133-44.
[http://dx.doi.org/10.1097/HJH.0000000000001299] [PMID: 28306634]
[12]
Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26(5): 331-42.
[http://dx.doi.org/10.1046/j.1365-2710.2001.00363.x] [PMID: 11679023]
[13]
Burnier M. Drug adherence in hypertension. Pharmacol Res 2017; 125(Pt B): 142-9.
[http://dx.doi.org/10.1016/j.phrs.2017.08.015] [PMID: 28870498]
[14]
Gallagher BD, Muntner P, Moise N, Lin JJ, Kronish IM. Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence? J Hypertens 2015; 33(5): 1108-13.
[http://dx.doi.org/10.1097/HJH.0000000000000503] [PMID: 25909704]
[15]
Jones ESW, Lesosky M, Blockman M, et al. Therapeutic drug monitoring of amlodipine and the Z-FHL/HHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension. S Afr Med J 2017; 107(10): 887-91.
[http://dx.doi.org/10.7196/SAMJ.2017.v107i10.12268] [PMID: 29022534]
[16]
de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol 2018; 84(1): 18-24.
[http://dx.doi.org/10.1111/bcp.13402] [PMID: 28815689]
[17]
Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147(5): 1311-20.
[http://dx.doi.org/10.1164/ajrccm/147.5.1311] [PMID: 8484650]
[18]
Wang Y, Kong MC, Ko Y. Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin. Thromb Haemost 2012; 108(4): 789-95.
[http://dx.doi.org/10.1160/TH12-05-0368] [PMID: 22836920]
[19]
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008; 10(5): 348-54.
[http://dx.doi.org/10.1111/j.1751-7176.2008.07572.x] [PMID: 18453793]
[20]
Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96(4) e5641
[http://dx.doi.org/10.1097/MD.0000000000005641] [PMID: 28121920]
[21]
Reynolds K, Viswanathan HN, O’Malley CD, et al. Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 2012; 46(5): 659-70.
[http://dx.doi.org/10.1345/aph.1Q652] [PMID: 22510666]
[22]
Azir SU, Hassali MA, Saleem F, Bashir S, Aljadhey H. Association between diabetes-related knowledge and medication adherence: results from cross-sectional analysis. Altern Ther Health Med 2016; 22: 8-13.
[23]
Yan J, You LM, Yang Q, et al. Translation and validation of a Chinese version of the 8-item Morisky medication adherence scale in myocardial infarction patients. J Eval Clin Pract 2014; 20(4): 311-7.
[http://dx.doi.org/10.1111/jep.12125] [PMID: 24813538]
[24]
Yang A, Wang B, Zhu G, et al. Validation of Chinese version of the Morisky medication adherence scale in patients with epilepsy. Seizure 2014; 23(4): 295-9.
[http://dx.doi.org/10.1016/j.seizure.2014.01.003] [PMID: 24484672]
[25]
Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens 2017; 35(12): 2346-57.
[http://dx.doi.org/10.1097/HJH.0000000000001502] [PMID: 28777133]
[26]
Butler MJ, Tanner RM, Muntner P, et al. Adherence to antihypertensive medications and associations with blood pressure among African Americans with hypertension in the Jackson Heart Study. J Am Soc Hypertens 2017; 11(9): 581-88.
[http://dx.doi.org/10.1016/j.jash.2017.06.011] [PMID: 28895842]
[27]
Kettani FZ, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40(1): 213-20.
[http://dx.doi.org/10.1161/STROKEAHA.108.522193] [PMID: 19038916]
[28]
Perreault S, Dragomir A, White M, Lalonde L, Blais L, Bérard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266(2): 207-18.
[http://dx.doi.org/10.1111/j.1365-2796.2009.02084.x] [PMID: 19623691]
[29]
Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120(16): 1598-605.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.830299] [PMID: 19805653]
[30]
Al-Daken LI, Eshah NF. Self-reported adherence to therapeutic regimens among patients with hypertension. Clin Exp Hypertens 2017; 39(3): 264-70.
[http://dx.doi.org/10.1080/10641963.2016.1247164] [PMID: 28448187]
[31]
Bandi P, Goldmann E, Parikh NS, Farsi P, Boden-Albala B. Age-related differences in antihypertensive medication adherence in hispanics: a cross-sectional community-based survey in New York city, 2011-2012. Prev Chronic Dis 2017; 14 E57
[http://dx.doi.org/10.5888/pcd14.160512] [PMID: 28704175]
[32]
Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24(6): 1193-200.
[http://dx.doi.org/10.1097/01.hjh.0000226211.95936.f5] [PMID: 16685222]
[33]
Bourgault C, Sénécal M, Brisson M, Marentette MA, Grégoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19(8): 607-13.
[http://dx.doi.org/10.1038/sj.jhh.1001873] [PMID: 15920457]
[34]
Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116(7): 737-44.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.669101] [PMID: 17646585]
[35]
Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336(7653): 1114-7.
[http://dx.doi.org/10.1136/bmj.39553.670231.25] [PMID: 18480115]
[36]
Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep 2000; 2(6): 515-24.
[http://dx.doi.org/10.1007/s11906-996-0035-6] [PMID: 11062596]
[37]
Costa FV. Improving adherence to treatment and reducing economic costs of hypertension: the role of olmesartan-based treatment. High Blood Press Cardiovasc Prev 2017; 24(3): 265-74.
[http://dx.doi.org/10.1007/s40292-017-0221-4] [PMID: 28695464]
[38]
Kociánová E, Václavík J, Tomková J, et al. Heart rate is a useful marker of adherence to beta-blocker treatment in hypertension. Blood Press 2017; 26(5): 311-8.
[http://dx.doi.org/10.1080/08037051.2017.1346458] [PMID: 28701047]
[39]
Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29(5): 972-84.
[http://dx.doi.org/10.1016/j.clinthera.2007.05.010] [PMID: 17697916]
[40]
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43(6): 521-30.
[http://dx.doi.org/10.1097/01.mlr.0000163641.86870.af] [PMID: 15908846]
[41]
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3): 290-300.
[http://dx.doi.org/10.1016/j.amjmed.2008.09.038] [PMID: 19272490]
[42]
Simonyi G, Ferenci T. [One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension]. Orv Hetil 2017; 158(42): 1669-73.
[http://dx.doi.org/10.1556/650.2017.30882] [PMID: 29037057]
[43]
Liakos CI, Papadopoulos DP, Kotsis VT. Adherence to treatment, safety, tolerance, and effectiveness of perindopril/amlodipine fixed-dose combination in greek patients with hypertension and stable coronary artery disease: a pan-hellenic prospective observational study of daily clinical practice. Am J Cardiovasc Drugs 2017; 17(5): 391-8.
[http://dx.doi.org/10.1007/s40256-017-0232-5] [PMID: 28466368]
[44]
Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med 2006; 145(3): 165-75.
[http://dx.doi.org/10.7326/0003-4819-145-3-200608010-00004] [PMID: 16880458]
[45]
Khalesi S, Irwin C, Sun J. Dietary patterns, nutrition knowledge, lifestyle, and health-related quality of life: associations with anti-hypertension medication adherence in a sample of australian adults. High Blood Press Cardiovasc Prev 2017; 24(4): 453-62.
[http://dx.doi.org/10.1007/s40292-017-0229-9] [PMID: 28884295]
[46]
Bhushan A, Fondell E, Ascherio A, Yuan C, Grodstein F, Willett W. Adherence to Mediterranean diet and subjective cognitive function in men. Eur J Epidemiol 2018; 33(2): 223-34.
[http://dx.doi.org/10.1007/s10654-017-0330-3] [PMID: 29147948]
[47]
Mahmoudian A, Zamani A, Tavakoli N, Farajzadegan Z, Fathollahi-Dehkordi F. Medication adherence in patients with hypertension: Does satisfaction with doctor-patient relationship work? J Res Med Sci 2017; 22: 48.
[http://dx.doi.org/10.4103/jrms.JRMS_205_16] [PMID: 28567067]
[48]
Kassavou A, Sutton S. Reasons for non-adherence to cardiometabolic medications, and acceptability of an interactive voice response intervention in patients with hypertension and type 2 diabetes in primary care: a qualitative study. BMJ Open 2017; 7(8) e015597
[http://dx.doi.org/10.1136/bmjopen-2016-015597] [PMID: 28801402]
[49]
Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339(27): 1957-63.
[http://dx.doi.org/10.1056/NEJM199812313392701] [PMID: 9869666]
[50]
Daugherty SL, Powers JD, Magid DJ, et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension 2012; 60(2): 303-9.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.192096] [PMID: 22733464]
[51]
Di Chiara T, Scaglione A, Corrao S, Argano C, Pinto A, Scaglione R. Education and hypertension: impact on global cardiovascular risk. Acta Cardiol 2017; 72(5): 507-13.
[http://dx.doi.org/10.1080/00015385.2017.1297626] [PMID: 28657499]
[52]
Kassavou A, Sutton S. Automated telecommunication interventions to promote adherence to cardio-metabolic medications: meta-analysis of effectiveness and meta-regression of behaviour change techniques. Health Psychol Rev 2018; 12(1): 25-42.
[PMID: 28805162]
[53]
Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 2000; 21(2): 153-60.
[http://dx.doi.org/10.1016/S0197-4580(99)00110-4] [PMID: 10867200]
[54]
Carmelli D, Swan GE, Reed T, Wolf PA, Miller BL, DeCarli C. Midlife cardiovascular risk factors and brain morphology in identical older male twins. Neurology 1999; 52(6): 1119-24.
[http://dx.doi.org/10.1212/WNL.52.6.1119] [PMID: 10214731]
[55]
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51(4): 1256-62.
[http://dx.doi.org/10.2337/diabetes.51.4.1256] [PMID: 11916953]
[56]
Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2003; 60(2): 223-8.
[http://dx.doi.org/10.1001/archneur.60.2.223] [PMID: 12580707]
[57]
Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol 1968; 12(1): 1-15.
[http://dx.doi.org/10.1007/BF00685305] [PMID: 5708546]
[58]
Waldstein SR, Elias MF. Introduction to the special section on health and cognitive function. Health Psychol 2003; 22(6): 555-8.
[http://dx.doi.org/10.1037/0278-6133.22.6.555] [PMID: 14640851]
[59]
Dolansky MA, Schaefer JT, Hawkins MA, et al. The association between cognitive function and objective adherence to dietary sodium guidelines in patients with heart failure. Patient Prefer Adherence 2016; 10: 233-41.
[PMID: 27042017]
[60]
Dolansky MA, Hawkins MA, Schaefer JT, et al. Association between poorer cognitive function and reduced objectively monitored medication adherence in patients with heart failure. Circ Heart Fail 2016; 9(12) e002475
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.116.002475] [PMID: 27895069]
[61]
Jankowska-Polańska B, Katarzyna L, Lidia A, Joanna J, Dudek K, Izabella U. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol 2016; 13(7): 559-65.
[PMID: 27605935]
[62]
Alosco ML, Spitznagel MB, Cohen R, et al. Better adherence to treatment recommendations in heart failure predicts improved cognitive function at a one-year follow-up. J Clin Exp Neuropsychol 2014; 36(9): 956-66.
[http://dx.doi.org/10.1080/13803395.2014.957167] [PMID: 25352233]
[63]
Joly L. Arterial stiffness and cognitive function. Geriatr Psychol Neuropsychiatr Vieil 2017; 15(1): 83-8.
[PMID: 28266345]
[64]
Iulita MF, Noriega de la Colina A, Girouard H. Arterial stiffness, cognitive impairment and dementia: confounding factor or real risk? J Neurochem 2018; 144(5): 527-48.
[http://dx.doi.org/10.1111/jnc.14235] [PMID: 28991365]
[65]
Zanoli L, Rastelli S, Inserra G, Castellino P. Arterial structure and function in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11304-11.
[http://dx.doi.org/10.3748/wjg.v21.i40.11304] [PMID: 26523102]
[66]
Kalaitzidis RG, Karasavvidou D, Tatsioni A, et al. Risk factors for cognitive dysfunction in CKD and hypertensive subjects. Int Urol Nephrol 2013; 45(6): 1637-46.
[http://dx.doi.org/10.1007/s11255-013-0450-y] [PMID: 23636430]
[67]
Karasavvidou D, Boutouyrie P, Kalaitzidis R, et al. Arterial damage and cognitive decline in chronic kidney disease patients. J Clin Hypertens (Greenwich) 2018; 20(9): 1276-84.
[http://dx.doi.org/10.1111/jch.13350] [PMID: 30006952]
[68]
Orkaby AR, Lunetta KL, Sun FJ, et al. Cross-sectional association of frailty and arterial stiffness in community-dwelling older adults: the framingham heart study. J Gerontol A Biol Sci Med Sci 2019; 74(3): 373-9.
[http://dx.doi.org/10.1093/gerona/gly134] [PMID: 29917058]
[69]
Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352(9137): 1347-51.
[http://dx.doi.org/10.1016/S0140-6736(98)03086-4] [PMID: 9802273]
[70]
Muela HCS, Costa-Hong VA, Yassuda MS, et al. Higher arterial stiffness is associated with lower cognitive performance in patients with hypertension. J Clin Hypertens (Greenwich) 2018; 20(1): 22-30.
[http://dx.doi.org/10.1111/jch.13129] [PMID: 29106057]
[71]
Triantafyllidi H, Arvaniti C, Lekakis J, et al. Cognitive impairment is related to increased arterial stiffness and microvascular damage in patients with never-treated essential hypertension. Am J Hypertens 2009; 22(5): 525-30.
[http://dx.doi.org/10.1038/ajh.2009.35] [PMID: 19265790]
[72]
Heffernan KS, Augustine JA, Lefferts WK, et al. Arterial stiffness and cerebral hemodynamic pulsatility during cognitive engagement in younger and older adults. Exp Gerontol 2018; 101: 54-62.
[http://dx.doi.org/10.1016/j.exger.2017.11.004] [PMID: 29129735]
[73]
Li X, Lyu P, Ren Y, An J, Dong Y. Arterial stiffness and cognitive impairment. J Neurol Sci 2017; 380: 1-10.
[http://dx.doi.org/10.1016/j.jns.2017.06.018] [PMID: 28870545]
[74]
Berni A, Ciani E, Cecioni I, Poggesi L, Abbate R, Boddi M. Adherence to antihypertensive therapy affects Ambulatory Arterial Stiffness Index. Eur J Intern Med 2011; 22(1): 93-8.
[http://dx.doi.org/10.1016/j.ejim.2010.07.015] [PMID: 21238902]
[75]
Sauder KA, Proctor DN, Chow M, et al. Endothelial function, arterial stiffness and adherence to the 2010 Dietary Guidelines for Americans: a cross-sectional analysis. Br J Nutr 2015; 113(11): 1773-81.
[http://dx.doi.org/10.1017/S0007114515000859] [PMID: 25885520]
[76]
van de Laar RJ, Stehouwer CD, van Bussel BC, Prins MH, Twisk JW, Ferreira I. Adherence to a Mediterranean dietary pattern in early life is associated with lower arterial stiffness in adulthood: the Amsterdam Growth and Health Longitudinal Study. J Intern Med 2013; 273(1): 79-93.
[http://dx.doi.org/10.1111/j.1365-2796.2012.02577.x] [PMID: 22809371]
[77]
Lydakis C, Stefanaki E, Stefanaki S, Thalassinos E, Kavousanaki M, Lydaki D. Correlation of blood pressure, obesity, and adherence to the Mediterranean diet with indices of arterial stiffness in children. Eur J Pediatr 2012; 171(9): 1373-82.
[http://dx.doi.org/10.1007/s00431-012-1735-3] [PMID: 22527567]
[78]
Karasavvidou D, Kalaitzidis R, Elisaf M. Arterial damage and cognitive impairment in patients with chronic kidney disease. J Clin Hypertens (Greenwich) 2018; 20(11): 1643.
[http://dx.doi.org/10.1111/jch.13402] [PMID: 30294959]
[79]
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15(8): 565-74.
[http://dx.doi.org/10.1002/pds.1230] [PMID: 16514590]
[80]
Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013; 51(8): 11-S21.
[http://dx.doi.org/10.1097/MLR.0b013e31829b1d2a] [PMID: 23774515]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 4
Year: 2020
Page: [410 - 417]
Pages: 8
DOI: 10.2174/1570161117666190415112953
Price: $65

Article Metrics

PDF: 13
HTML: 1